tetano
Editor, Senior Moderator
Open Forum Infect Dis
. 2024 Aug 27;11(9)
fae462.
doi: 10.1093/ofid/ofae462. eCollection 2024 Sep. Postacute Sequelae of COVID (PASC or Long COVID): An Evidenced-Based Approach
Daniel O Griffin[SUP] 1 [/SUP]
Affiliations
While the acute manifestations of infectious diseases are well known, in some individuals, symptoms can either persist or appear after the acute period. Postviral fatigue syndromes are recognized with other viral infections and are described after coronavirus disease 2019 (COVID-19). We have a growing number of individuals with symptoms that persist for weeks, months, and years. Here, we share the evidence regarding the abnormalities associated with postacute sequelae of COVID-19 (PASC) and therapeutics. We describe physiological and biochemical abnormalities seen in individuals reporting PASC. We describe the several evidence-based interventions to offer patients. It is expected that this growing understanding of the mechanisms driving PASC and the benefits seen with certain therapeutics may not only lead to better outcomes for those with PASC but may also have the potential for understanding and treating other postinfectious sequelae.
Keywords: COVID-19; PASC; SARS-CoV-2; long COVID; postacute sequelae of COVID.
. 2024 Aug 27;11(9)
fae462.doi: 10.1093/ofid/ofae462. eCollection 2024 Sep. Postacute Sequelae of COVID (PASC or Long COVID): An Evidenced-Based Approach
Daniel O Griffin[SUP] 1 [/SUP]
Affiliations
- PMID: 39220656
- PMCID: PMC11363684
- DOI: 10.1093/ofid/ofae462
While the acute manifestations of infectious diseases are well known, in some individuals, symptoms can either persist or appear after the acute period. Postviral fatigue syndromes are recognized with other viral infections and are described after coronavirus disease 2019 (COVID-19). We have a growing number of individuals with symptoms that persist for weeks, months, and years. Here, we share the evidence regarding the abnormalities associated with postacute sequelae of COVID-19 (PASC) and therapeutics. We describe physiological and biochemical abnormalities seen in individuals reporting PASC. We describe the several evidence-based interventions to offer patients. It is expected that this growing understanding of the mechanisms driving PASC and the benefits seen with certain therapeutics may not only lead to better outcomes for those with PASC but may also have the potential for understanding and treating other postinfectious sequelae.
Keywords: COVID-19; PASC; SARS-CoV-2; long COVID; postacute sequelae of COVID.